We’re following the science at #ERSCongress with our commitment to advance research on the role of the epithelium in #severeasthma. Our ambition is to improve the lives of patients, many of whom still struggle to control their symptoms. https://t.co/TI7GQOlZAB pic.twitter.com/7wcX0bl7GL
— AstraZeneca (@AstraZeneca) September 8, 2020
#Cancer doesn’t stop during the #COVID19 pandemic and neither do we. As #ESMO20 moves to a virtual format, we continue our pursuit of advancing precision medicine with 114 abstracts across four of our oncology platforms to be presented during the event pic.twitter.com/V9UhcqGlVK
— AstraZeneca (@AstraZeneca) September 8, 2020
What is eosinophilic immune dysfunction? It's the dysregulation of biological mechanisms involved in eosinophil recruitment & activation that allows eosinophils to infiltrate patients’ tissue and to potentially drive inflammatory disease. Learn more: #UncoverEID #ERSCongress pic.twitter.com/c5boWvhwNB
— AstraZeneca (@AstraZeneca) September 7, 2020
No cure currently exists for #CKD, but disease progression can be slowed through lifestyle changes and current treatments. As we look at the causes and comorbidities, we aim to work with healthcare professionals to help to manage this serious disease. pic.twitter.com/hyr4TfMlNv
— AstraZeneca (@AstraZeneca) September 3, 2020
As the prevalence and burden of #heartfailure rises globally, we continue to search for new ways to improve prevention, diagnosis and care to help change the outlook for millions affected by this devastating disease. #ESCCongress https://t.co/AfQ3XTwn3O pic.twitter.com/5DYIhnzjjB
— AstraZeneca (@AstraZeneca) September 1, 2020
In a new @NatureChemistry paper with @scrippsresearch, we show the potential of targeting RNA with small molecules. Designing small molecules capable of interacting with and modulating RNA, could open new avenues to target challenging disease pathways. https://t.co/adG4VRFKlz pic.twitter.com/J7cPe63Lyv
— AstraZeneca (@AstraZeneca) August 26, 2020
For the 500,000+ people with living with dialysis-dependent end-stage #kidneydisease in the US, hyperkalaemia is a common, yet potentially life-threatening complication. pic.twitter.com/wgfzjOjdcm
— AstraZeneca (@AstraZeneca) August 19, 2020
Through our expansive efforts to address the #COVID19 pandemic, our unique culture can be seen in action. In addition to our R&D work, we have taken philanthropic measures to assist where needed and identified solutions to meets the needs of our employees during this crisis. pic.twitter.com/rrd3Tx0aWT
— AstraZeneca (@AstraZeneca) July 31, 2020
Preventing #COPD exacerbations could have a life-changing impact. Here’s how we’re increasing our understanding of COPD so that we can help tackle this public health burden: https://t.co/AN8k2tvSQf pic.twitter.com/zEruxiCpxr
— AstraZeneca (@AstraZeneca) July 28, 2020
#Heartfailure has a survival rate similar to some common cancers in both men (prostate & bladder cancers) and women (breast cancers). It is pivotal we work with healthcare professionals to help improve outcomes for people living with heart failure. https://t.co/BHhiOA60cW pic.twitter.com/6Q4FYy0ZWQ
— AstraZeneca (@AstraZeneca) July 25, 2020
The fate of any cell is determined by the balance of pro-survival and pro-death proteins. We’re exploring the role of ‘programmed cell death’ in cancer biology to outsmart #cancer cells. #AACR20 pic.twitter.com/t8aQ8ITW8Q
— AstraZeneca (@AstraZeneca) June 26, 2020
Digital and technology solutions are enabling R&D to operate effectively during the #COVID19 pandemic by keeping our clinical trials on track, ensuring a positive patient experience within our trials and enabling R&D colleagues to stay connected: https://t.co/cgzXQu9xhq pic.twitter.com/QIoy5Zepkt
— AstraZeneca (@AstraZeneca) June 17, 2020
Quarantine & social distancing can make it difficult for #type2diabetes patients to regulate glucose levels. With the increased risk of complications such as #HF for these patients, we´re prioritising our research to help HCPs prevent early cardiovascular complications. #ADA2020 pic.twitter.com/Wokfy3t92C
— AstraZeneca (@AstraZeneca) June 16, 2020
People with #T2D are twice as likely to develop #cardiovascular disease but often remain on suboptimal regimens to manage risks. We are collaborating with HCPs to help improve outcomes for people with #type2diabetes and associated risks. #ADA2020 https://t.co/2clkWnFKnL pic.twitter.com/rLs4L7AvWm
— AstraZeneca (@AstraZeneca) June 14, 2020
We have reached an agreement with the Inclusive Vaccines Alliance to supply up to 400 million doses of @UniofOxford’s potential #COVID19 vaccine to Europe at no profit https://t.co/eVXJs66S3b pic.twitter.com/yBRr5GRC56
— AstraZeneca (@AstraZeneca) June 13, 2020
In our ambition to discover and develop monoclonal antibodies that recognise, bind to and neutralise the SARS-CoV-2 virus, we have signed new agreements with academia and US government agencies and plan to progress a combination approach: https://t.co/miiar9rLcT pic.twitter.com/01X4CvFJUA
— AstraZeneca (@AstraZeneca) June 9, 2020
#CKD is often not diagnosed until it is advanced. The timeliness of the diagnosis also affects the prevalence of complications including anaemia, which worsens with declining kidney function. https://t.co/pG21x93cFh #ERAEDTA20 pic.twitter.com/niItdJOvOo
— AstraZeneca (@AstraZeneca) June 8, 2020
At the heart of our core values is to “follow the science” and we are committed to adhere to the highest scientific and clinical standards as we research a potential #COVID19 vaccine. @Sanofi will you join us as #WeStandWithScience? https://t.co/uEaOpNBba8 pic.twitter.com/WgJestzs3D
— AstraZeneca (@AstraZeneca) September 8, 2020
It can be tough to #SpotLeukaemia early because symptoms resemble other common illnesses. If you feel worried, don’t delay seeing your doctor because of the pandemic. #WLD20 https://t.co/G5fUIrtjyv pic.twitter.com/yvG46aplcy
— AstraZeneca (@AstraZeneca) September 4, 2020
In a new LabTalk blog, Li-Ming Gan describe how measuring blood flow restrictions in arteries using Fractional Flow Reserve can improve guidance for stent procedures in #heartdisease and offers a potential new endpoint for clinical trials: https://t.co/wf2EX3tHU8 pic.twitter.com/81hQLWePpB
— AstraZeneca (@AstraZeneca) September 9, 2020
We're committed to the millions of people whose illness may be driven by eosinophils as a result of eosinophilic immune dysfunction. Learn more & #UncoverEID: https://t.co/jlf2dhBgIX. #ERSCongress pic.twitter.com/RjlfM3HQLi
— AstraZeneca (@AstraZeneca) September 8, 2020
Our ambition is to help improve outcomes for the millions of people living with severe asthma, COPD and other eosinophil-driven diseases. Our research being presented at #ERSCongress helps us get one step closer to transforming patient care. https://t.co/ugLazSX8Uw pic.twitter.com/Z4xcQwTLCy
— AstraZeneca (@AstraZeneca) September 7, 2020
Minimising off-target effects of #CRISPR gene editing will be crucial for potential therapeutic use in the future. In a new blog, Ben Taylor explains the inspiration behind CRISPR GUARD, a novel tool for reducing off-target mutations. https://t.co/18sCTTMP54 pic.twitter.com/2g7Xzv0Vep
— AstraZeneca (@AstraZeneca) September 7, 2020
How do we drive scientific discovery? Collaborations like the Antibody Alliance Laboratory with @CR_UK help us advance new approaches to targeting disease – and support people with #cancer everywhere. https://t.co/amtcseTbDb
— AstraZeneca (@AstraZeneca) September 3, 2020
We’re partnering with @GA2P2 to launch a public health campaign to raise awareness among people with #asthma of the risks associated with over-reliance on blue reliever (SABA) inhalers. Learn more about why this is important: https://t.co/uiFz6oHPY3 #BreakOverReliance pic.twitter.com/BZO3RswZcQ
— AstraZeneca (@AstraZeneca) September 1, 2020
Together with industry and academic partners we are leading the new @IMI_JU PREMIER project, aiming to help the pharmaceutical industry better model the environmental risks of Active Pharmaceutical Ingredients (APIs) and explore greener drug development. https://t.co/QSm0FavP8l pic.twitter.com/vBYFv3nTW3
— AstraZeneca (@AstraZeneca) September 1, 2020
People with #heartfailure are at risk of hyperkalaemia. High potassium can be life-threatening, but improved management can help improve patient outcomes. #ESCCongress https://t.co/xW1Ms5fGWd pic.twitter.com/alSzuFKpaq
— AstraZeneca (@AstraZeneca) August 31, 2020
#Cardiovascular disease is a chronic and persistent condition and the leading cause of mortality worldwide. At #ESCCongress we’re sharing our latest research on long-term cardiovascular risk management. https://t.co/cSW4ZUKiTk pic.twitter.com/WzpaKk5VwL
— AstraZeneca (@AstraZeneca) August 29, 2020
Early detection of kidney disease is vital to help prevent or slow disease progression. Here’s what Kevin Fowler @gratefull080504, a patient living with #CKD teaches us about patient advocacy. https://t.co/sIOi8oTd38 pic.twitter.com/tiqbop2oka
— AstraZeneca (@AstraZeneca) August 11, 2020
We’re committed to improving the standard of care in #COPD, a progressive disease that affects 384 million people globally. Learn more: https://t.co/Ad6a3c57Kz. #ATS2020 pic.twitter.com/oD2YtI75hK
— AstraZeneca (@AstraZeneca) August 8, 2020
Our new @Nature paper with @LeonoriLab @OfficialUoM describes a novel chemical process for efficiently producing anilines, which are important molecules in drug discovery. This has the potential to simplify the synthesis of a wide range of drug molecules: https://t.co/29o4azdqjY pic.twitter.com/lE7z059tcq
— AstraZeneca (@AstraZeneca) August 7, 2020
We’re committed to advancing the understanding of the role of eosinophils in inflammatory diseases like severe asthma and nasal polyps, with the aim to improve diagnosis, patient referrals and timely, appropriate treatment. https://t.co/bI3Tmuap0g #ATS2020 pic.twitter.com/7ypDBeahws
— AstraZeneca (@AstraZeneca) August 6, 2020
We’re following the science to better understand the important role of eosinophils as key effector cells in a range of potentially devasting inflammatory diseases including chronic rhinosinusitis with nasal polyps (CRSwNP). #ATS2020 pic.twitter.com/o36XLOZfwt
— AstraZeneca (@AstraZeneca) August 6, 2020
We are collaborating with healthcare technology company, @_ekoai to drive forward their ambition to simplify and democratise echocardiography to transform the standard of care for people living with or at risk for #heartfailure. pic.twitter.com/zcPRNibVqb
— AstraZeneca (@AstraZeneca) August 5, 2020
José Baselga participated in a panel for the #AACRCovid and Cancer virtual meeting to discuss the impact of the #COVID19 pandemic on clinical trials. Click through for his takeaways, including how disruption is an opportunity for change. https://t.co/R4UlkfYdzR pic.twitter.com/wlFPJeQuTl
— AstraZeneca (@AstraZeneca) August 5, 2020
As the COVID-19 pandemic continues worldwide, it’s more important than ever that we ensure we’re protecting our most vulnerable patients from other respiratory illnesses, including respiratory syncytial virus. #RSV https://t.co/D6QGsvQsMt
— AstraZeneca (@AstraZeneca) August 3, 2020
Collaboration in the #lungcancer community is vital to improving outcomes for patients #livingwithlungcancer. This #WLCD2020, we’re proud to stand with other industry leaders committed to raising standards for patients in need of better screening, diagnosis and treatment. #LCSM https://t.co/q5AM83uvSA
— AstraZeneca (@AstraZeneca) August 1, 2020
Transforming patient care worldwide on #WLCD2020: The inaugural Initiatives in #LungCancer Care awards span six continents and use a variety of strategies to support patients through their cancer treatment journey. #LungAmbition #livingwithlungcancer https://t.co/usaROFSg91 pic.twitter.com/srJkHCN2P2
— AstraZeneca (@AstraZeneca) August 1, 2020
Today we’re sharing results from a strong first half, in addition to progress made in our scientific pursuit to address the #COVID19 pandemic. https://t.co/Hr53PyaXmh $AZN pic.twitter.com/ycbqRAjRwe
— AstraZeneca (@AstraZeneca) July 30, 2020
Antibody-drug conjugates (ADCs) are an exciting area of development in #oncology. But how exactly do they deliver chemotherapy to #cancer cells? See a quick walkthrough: the ABCs of ADCs. #ScienceFromAtoZ pic.twitter.com/rJRGjBa8Si
— AstraZeneca (@AstraZeneca) July 27, 2020
#COVID19 should never stop anyone from seeking help in an emergency. If you have symptoms of a heart attack or stroke, seek help immediately. More advice here: https://t.co/6HPULPNC4c #UseYourHeart pic.twitter.com/GqmI1eJRVI
— AstraZeneca (@AstraZeneca) July 10, 2020
The impact of #COPD exacerbations should not be underestimated. Hear from Colin and Stephanie on what it can really feel like to experience an exacerbation. We’re following the science with bringing positive change for such patients at front of mind. #ATS2020 pic.twitter.com/XVep8S1cB7
— AstraZeneca (@AstraZeneca) June 21, 2020
With few existing therapies, people living with #lupus can experience many unmet needs. By following the science in immunology-driven diseases, researchers are uncovering insights that may help patients better manage this disease. #EULAR2020 #EULAR2020goesvirtual pic.twitter.com/V8PkEV3DKx
— AstraZeneca (@AstraZeneca) June 4, 2020
We are collaborating with @accent_tx to discover, develop & commercialise RNA-modifying proteins, with the aim of using this #epigenetic approach to identify novel targets and unlock the full potential of our #cancer medicines. https://t.co/2e51k2gcMj pic.twitter.com/QjYmHe1BuF
— AstraZeneca (@AstraZeneca) June 4, 2020
Managing #lupus remains challenging, but research into the disease drivers is helping identify new approaches to help people manage this debilitating condition. #LupusAwarenessMonth pic.twitter.com/zMICa7lHTg
— AstraZeneca (@AstraZeneca) May 31, 2020
Traditionally HER2 status has been categorised as either positive or negative based on the amount of #HER2 protein and the number of copies of the HER2 gene in the cancer cells. #ASCO20 pic.twitter.com/ragI5USlji
— AstraZeneca (@AstraZeneca) May 30, 2020
We agree the time to act is now, to secure our future and to prosper by putting people and planet at the heart of global value creation. We are pleased to support #TheGreatReset, @wef https://t.co/eIyZbPs4dP
— AstraZeneca (@AstraZeneca) June 4, 2020
We're excited to announce a global collaboration with @AstraZeneca to accelerate the development of digital health tools for the earlier screening of cardiovascular diseases, including heart failure. #healthcare #healthtech #digitalhealth #heartdisease https://t.co/8JI9SM0IdO pic.twitter.com/hXep8bWfB4
— eko_health (@Eko_Health) August 4, 2020
Vaccines are one of our most effective public health tools 🔬
Today, we announced our partnership with @AstraZeneca to support the manufacture of 300 million doses of their #COVID19 vaccine candidate, AZD1222.
👉https://t.co/aLr1QcQts9 pic.twitter.com/4FJhvh1UaR
— CEPI (@CEPIvaccines) June 4, 2020
WHF Emerging Leader Dr Sarah Kraus explains the importance of improving awareness of #heartfailure, following the publication of the #HFGap report in collaboration @AstraZeneca. ➡️ https://t.co/MN623bhHX6 pic.twitter.com/EfC3Cqt1cD
— World Heart Federation (@worldheartfed) July 13, 2020
Working with @AstraZeneca, we surveyed people and policymakers around the world to understand their awareness of #heartfailure and its impact on health systems. Read the #HFGap report to find out more ➡️ https://t.co/MN623bzjlG pic.twitter.com/68lT1TcnzN
— World Heart Federation (@worldheartfed) July 9, 2020
📢 The Daily Congress Bulletin issue n. 2 is online!
Read it here https://t.co/eJRlfOEark#ERAEDTA20 #eraedta #congressbulletin pic.twitter.com/G23iXPRmpA— ERA-EDTA (@ERAEDTA) June 6, 2020
Do you know the 3 steps to testing #lungcancer? Follow through with #biomarker testing for a complete diagnosis. Learn more at https://t.co/j4CumIFV2n #MyFollowThrough #LCSM pic.twitter.com/umRr98DmlP
— AstraZenecaUS (@AstraZenecaUS) September 10, 2020
Thanks @KennyEdmonds for sharing what following through means to you! Learn more about following through for #biomarker testing in #lungcancer at https://t.co/PAKGOLpEXA and share your own follow-through using #MyFollowThrough. https://t.co/Kb559T1BeA
— AstraZenecaUS (@AstraZenecaUS) September 4, 2020
Though chronic kidney disease (CKD) is associated with significant patient morbidity, many patients living with #CKD are underdiagnosed. Read more from the @KidneyFund on our blog about how we should reimagine management of the condition #ESCcongress
— AstraZenecaUS (@AstraZenecaUS) September 2, 2020
We, along with @sciam, are excited to announce the second annual #C2Awards finalists! Advancing oncology is a community effort – join us in celebrating this group of cancer care heroes: https://t.co/b0wMm2PCue pic.twitter.com/eWwMyuno1M
— AstraZenecaUS (@AstraZenecaUS) August 27, 2020
Let’s check-in with 2019 #C2Awards President’s Award winner, the @ocrahope Survivors Teaching Students (STS) program. Audra Moran tells us how winning has helped STS expand as part of a podcast series with @sciam: https://t.co/1ly2R9aBgv
— AstraZenecaUS (@AstraZenecaUS) August 24, 2020
We're inspired by @JillianMichaels lifelong mission to encourage healthier decisions… and we believe #biomarker testing for #lungcancer is one of them. Learn more at https://t.co/0FWtlzKR4X, and share your own follow-through using #MyFollowThrough. https://t.co/J8IHWLT5En
— AstraZenecaUS (@AstraZenecaUS) August 19, 2020
Jason Day and his mom know first-hand why #biomarker testing is important to understanding your Stage IV #NSCLC diagnosis. Thanks @JDayGolf for sharing why you’re an advocate for biomarker testing. Share your own follow-through using #MyFollowThrough! #LCSM https://t.co/E1WjKBwhan
— AstraZenecaUS (@AstraZenecaUS) August 14, 2020
Today, we began shipment of our flu vaccine that will be distributed in the US, which includes over 25% more doses than anticipated for the season. Learn more here: https://t.co/2P22WvK9KW pic.twitter.com/R1MwDmQE7A
— AstraZenecaUS (@AstraZenecaUS) August 13, 2020
We joined with our partners at @AllergyAsthmaHQ and @APFEDorg to speak with asthma sufferer, Tony Hale, on why he feels educating others about personalized asthma care is important – check out his story here: https://t.co/SoLWujvbVv pic.twitter.com/KjYpqGpY73
— AstraZenecaUS (@AstraZenecaUS) August 11, 2020
We’re pleased to announce that the @US_FDA has granted breakthrough therapy designation for the ADAURA trial in the adjuvant treatment of patients with early-stage EGFR-mutated NSCLC after complete tumor resection with curative intent. Learn more: https://t.co/5ayQLDRWRr pic.twitter.com/4aZuiuLHEg
— AstraZenecaUS (@AstraZenecaUS) July 30, 2020
Dr. John Pagel, hematologist and oncologist at @Swedish, reflects on the long-term data presented at #ASCO20 and #EHA25Virtual and the importance of understanding and addressing blood cancer patients’ needs. https://t.co/0jAPXI3P8I
— AstraZenecaUS (@AstraZenecaUS) July 29, 2020
#DYK COPD is the fourth leading cause of death in the U.S.? Learn more about a new treatment option that is offering #COPD patients more hope: https://t.co/OaTaGIsgBe pic.twitter.com/FeRBYuBuul
— AstraZenecaUS (@AstraZenecaUS) July 25, 2020
It’s through the tireless work of patient advocacy groups like @knowyournodes that we can tackle the gaps in critical information for all lymphoma patients, including those living with #CLL. Hear from their CEO Lorna Warwick: https://t.co/DP3w3MPpr2
— AstraZenecaUS (@AstraZenecaUS) July 24, 2020
Today, the US FDA granted Fast Track designation for the development of our therapy option to reduce the risk of hospitalization for #heartfailure or #CV death in adults following an acute myocardial infraction or heart attack. Learn more: https://t.co/BdZlIUrScU pic.twitter.com/tUVVvicGAV
— AstraZenecaUS (@AstraZenecaUS) July 16, 2020
SHARE THE FACTS with everyone you know during #OvarianCancerAwarenessMonth. Learn more here: https://t.co/fF7a6brrDD #FactOfTheDay pic.twitter.com/PvfWIFUq7b
— Ovarian Cancer Research Alliance (@ocrahope) September 3, 2020
Did you know 1 in 9 men in the United States will be diagnosed with #ProstateCancer during their lifetime? Early detection is key to living prostate cancer free so talk to your doctor about screening for prostate cancer.https://t.co/DF1ZjzdM5b pic.twitter.com/eVYIcuPtES
— Urology Care Fdn. (@UrologyCareFdn) September 1, 2020
Thank you to @AstraZenecaUS, @SanofiUS and @PhRMA for joining us this morning for the first episode of the Jumpstart American Jobs Series. In case you missed it, you can watch here: https://t.co/ZMFcwD56So pic.twitter.com/vE0kpxfHqs
— Global Business Alliance (@GlobalBiz) July 13, 2020